Evidence map›Paper›PMID 41241877›Full record

ArticleEuropean radiology experimental2025

Intra- and inter-tumoural heterogeneity in von Hippel-Lindau disease-related renal cancer: a multimodal data study protocol.

Isaline Rowe, Alberto Colombo, Francesca Corea, Francesco Pisu, Francesca Genova, Martina Uggé, Chiara Ciaparrone, Antonino Giangrasso, Giovanni B Pipitone, Giulia M Scotti and 15 more

Abstract read
In one paragraph

Article in European radiology experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Isaline Rowe *Comprehensive Cancer Center/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy. rowe.isaline@hsr.it.ORCID http://orcid.org/0000-0002-5398-1776
Alberto Colombo *San Raffaele AI Center (S-RACE), Vita-Salute San Raffaele University, Milan, Italy.
Francesca CoreaVita-Salute San Raffaele University, Milan, Italy.
Francesco PisuSan Raffaele AI Center (S-RACE), Vita-Salute San Raffaele University, Milan, Italy.
Francesca GenovaCenter for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy.
Martina UggéComprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milan, Italy.
Chiara CiaparronePathology Unit, AOU San Giovanni di Dio e Ruggi d'Aragona "Scuola Medica Salernitana", Salerno, Italy.
Antonino GiangrassoPathology Unit, AOU San Giovanni di Dio e Ruggi d'Aragona "Scuola Medica Salernitana", Salerno, Italy.
Giovanni B PipitoneLaboratory of Clinical Molecular Genetics, IRCCS Ospedale San Raffaele, Milan, Italy.
Giulia M ScottiCenter for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy.
Alessandro LarcherComprehensive Cancer Center/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy.
Giorgia ColciagoComprehensive Cancer Center/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy.
Marco J MorelliCenter for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy.
Roberta LucianòDepartment of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy.
Paola CarreraLaboratory of Clinical Molecular Genetics, IRCCS Ospedale San Raffaele, Milan, Italy.
Pio ZeppaUrology Unit, AOU San Giovanni di Dio e Ruggi d'Aragona "Scuola Medica Salernitana", Salerno, Italy.
Alessandro CaputoUrology Unit, AOU San Giovanni di Dio e Ruggi d'Aragona "Scuola Medica Salernitana", Salerno, Italy.
Roberto BertiniComprehensive Cancer Center/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy.
Francesco MontorsiComprehensive Cancer Center/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy.
Andrea SaloniaComprehensive Cancer Center/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy.
Paolo VerzeUrology Unit, AOU San Giovanni di Dio e Ruggi d'Aragona "Scuola Medica Salernitana", Salerno, Italy.
Anna PalmisanoVita-Salute San Raffaele University, Milan, Italy.
Antonio EspositoVita-Salute San Raffaele University, Milan, Italy.
Rosa BernardiComprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milan, Italy.
Umberto CapitanioComprehensive Cancer Center/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy. capitanio.umberto@hsr.it.

Funding

European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS PNRR-MR1-2022-12375818
6 · The paper itself

Abstract

von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome caused by germline pathogenic variants in the VHL gene. The current standard of care primarily involves surgical resection, which is arbitrarily recommended for renal tumours ≥ 3 cm to reduce the risk of metastasis. However, this approach often leads to repeated surgeries and increased patient morbidity. The key unmet clinical need for VHL patients is the ability to predict the most appropriate therapeutic strategy and the optimal timing for surgical intervention on an individualised basis. Here, we describe a methodology designed to create an integrated map of intra- and inter-tumour heterogeneity in VHL-associated clear cell renal cell carcinoma by combining radiomics, histology, RNA sequencing, whole genome sequencing, and patient-derived organoid cultures from multi-regional tumour biopsies. We hypothesise that decoding this heterogeneity through an integrated analysis of imaging, histopathology, and molecular profiling will enhance diagnostic accuracy and enable more informed and personalised therapeutic decisions for VHL patients. RELEVANCE STATEMENT: Due to the current lack of biological or molecular markers assisting clinical decision-making, VHL patients undergo multiple surgical interventions with an incremental risk of complications and morbidity. We expect that our multimodal data study protocol will give tools to guide clinical management. KEY POINTS: Multiregional needle biopsies enable comprehensive analysis even in small ccRCC. Imaging characteristics suggest the presence of intra- and inter-lesion heterogeneity. Tumours are clonally independent and harbour distinct chromosome 3p loss events. Tumours display both intra- and inter-tumour transcriptomics heterogeneity. Patient-derived organoids grow more easily from areas of low tumour density.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMultimodal Imagingvon Hippel-Lindau DiseaseHumansCarcinoma (renal cell)Magnetic resonance imagingMultiomicsOrganoidsvon Hippel–Lindau disease

Identifiers

PMID41241877
PMCPMC12620338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.